ArticleiScience2026
Free-floating long-term vascularized mesenchymal organoids.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vasculature is essential for tissue function and pathology. Spheroid co-cultures of endothelial and marrow/mesenchymal stromal/stem cells (MSCs) form consistent structures, but the vascular components are short-lived. iPSC-derived vascular organoids can establish complex vasculature but often have variable cell maturation and low reproducibility. This article presents consistently formed, free-floating, long-term vascularized mesenchymal organoids (VMOs), by co-culturing human umbilical vein endothelial cells (HUVECs) and MSCs in a pre-gelled minimal Matrigel scaffold. VMOs support 60-day stable vasculature, exhibiting tissue maturation involving inflammation, extracellular matrix remodeling, and endothelial development. Compared to traditional spheroids, VMOs showed enhanced vascular complexity, sustained extracellular matrix production, and higher cell viability. The system preserved MSC heterogeneity including perivascular cell types, offering physiological relevance. Engraftment of breast cancer cells revealed stromal-tumor niches, enabling modeling of bone marrow metastasis. This robust platform offers an alternative model for studying vascular biology, stromal dynamics, and cancer progression, with potential applications in drug testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.